{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["gemcitabine","cisplatin","nab-paclitaxel"]],"indication":"resectable high-risk intrahepatic cholangiocarcinoma","name":"NCT03579771","nct_id":"NCT03579771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03579771. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.","label":"Gemcitabine, cisplatin, nab-paclitaxel","type":"EXPERIMENTAL"}],"collaborators":["Celgene","National Institutes of Health (NIH)","National Cancer Institute (NCI)"],"completion_date":{"date":"2023-09-16","type":"ACTUAL"},"conditions":["Resectable Cholangiocarcinoma","Stage IB Intrahepatic Cholangiocarcinoma AJCC v8","Stage II Intrahepatic Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8"],"enrollment":{"count":30,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cisplatin","otherNames":["CDDP","Cis-diamminedichloridoplatinum","Cismaplat","Cisplatinum","Neoplatin","Platamin","Platinol"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["dFdCyd","Difluorodeoxycytidine hydrochloride","Gemcitabine hydrochloride","Gemzar"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["ABI-007","Abraxane","Nanoparticle albumin-bound paclitaxel"],"type":"DRUG"}],"last_update":"2025-08-15","lead_sponsor":"Emory University","official_title":"A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Who Completed All Preoperative and Operative Therapy","timeFrame":"Up to 12 weeks after study start"},{"measure":"Number of Participants With Adverse Events","timeFrame":"Up to 3 years after study start"}],"references":[],"start_date":{"date":"2018-09-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer","url":"https://clinicaltrials.gov/study/NCT03579771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03579771"}